Gilead Sciences (GILD)

Tempus AI (TEM) shares up 3.6% on expanded Gilead oncology deal. Explore technical support levels, ALERT trial success, and analyst ratings.

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total consideration of up to $5 billion. This strategic maneuver, consisting of $3.15 billion in upfront cash and

Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with data, analytics and drug development.

Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook.

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2, the offer has now been pushed back to April 24, 2026. This delay, while framed as a standard procedural

Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines for approximately $2.175 billion. The deal marks Gilead’s second massive investment in the immunology sector within a

With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener.

This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale.

Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.

As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic $813.3 billion, a massive 50% increase over the same period last year. This record-breaking figure

Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead ...

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

It's important to always be prepared.

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Compugen (CGEN) Q4 2025 Earnings Call Transcript

Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market.